The function of this paper is to look at the connection between happiness at work and cross-selling efficiency within the banking sector. In addition, the mediating impact of service-skill use is analyzed within the relationship between happiness at work and efficiency.
Confirmatory issue evaluation is utilized by means of structural equation fashions to evaluate the connection between happiness at work, service-skill use, and cross-selling efficiency. A pattern of 492 monetary service workers is examined. Results reveal that happiness at work positively and immediately impacts cross-selling efficiency. The examine additionally exhibits that service-skill use performs a partial mediating position within the relationship between happiness at work and cross-selling efficiency.
This analysis expands the speculation of the completely happy productive employee perspective based mostly on the job demands-resources mannequin and defines and conceptualizes service-skill use. Employees who’re happier at work cross-sell higher, however their service-skill use mediates the impact of happiness at work maxanim on cross-selling efficiency.
Previous experimental psychology research based mostly on visible search paradigms have reported that younger adults detect emotional facial expressions extra quickly than emotionally impartial expressions. However, it stays unclear whether or not this holds in older adults.
We investigated this by evaluating the talents of younger and older adults to detect emotional and impartial facial expressions whereas controlling the visible properties of faces introduced (termed anti-expressions) in a visible search process. Both age teams detected regular indignant faces extra quickly than anti-angry faces.
However, whereas younger adults detected regular completely happy faces extra quickly than anti-happy faces, older adults didn’t. This means that older adults will not be simple to detect or focusing consideration in direction of smiling faces showing peripherally.
Many research have proven that not solely threatening but in addition constructive stimuli seize visible consideration. However, within the dot-probe process, a typical paradigm to evaluate consideration to emotional stimuli, often no bias in direction of completely happy faces happens. Here, we investigated whether or not such a bias can happen and, in that case, below which situations.
In Experiment 1, we investigated whether or not the bias is contingent on the simultaneous presentation of distractor stimuli with the targets. Participants carried out a dot-probe process with both stand-alone targets or targets that had been accompanied by distractors. We discovered an attentional bias in direction of completely happy faces that was not moderated by goal sort.
To rule out perceptual low-level confounds because the trigger of the bias in direction of completely happy faces, Experiments 2a and 2b comprised dot-probe duties with inverted face cues. No attentional bias in direction of inverted completely happy faces occurred.
In Experiment 3, we investigated whether or not a bias in direction of completely happy faces is contingent on a social-processing mode. Participants carried out a dot-probe process with socially significant (schematic faces) or socially meaningless (scrambled schematic faces) targets. Again, a bias in direction of completely happy faces, which was not moderated by goal sort, occurred.
In Experiment 4, we investigated the attentional bias in direction of completely happy faces when one other extremely related expression was current. Participants carried out a dot-probe process with each completely happy and indignant face cues. A big attentional bias in direction of emotional faces occurred that didn’t differ between each cue feelings. These outcomes recommend that completely happy faces are sufficiently related for observers to seize consideration within the dot-probe process.
The frontline therapy choices for sufferers with metastatic renal cell carcinoma (mRCC) are evolving quickly because the approval of mixture immunotherapies by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA). In explicit, together with vascular endothelial progress issue receptor (VEGFR) tyrosine-kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs) have considerably improved the result of sufferers with mRCC in comparison with TKI monotherapy.
Here, we assessment the preclinical knowledge supporting the mixture of ICIs with VEGFR TKIs. The VEGF-signaling inhibition might ideally maintain immunotherapy by a constructive modulation of the tumor microenvironment (TME). Antiangiogenetics, actually, with their inhibitory exercise on myelopoiesis that not directly reduces myeloid-derived suppressor cells (MDSCs) and regulatory T cells’ (Tregs) frequency and performance, might have a job in figuring out an efficient anti-tumor immune response. These findings are related for the challenges posed to clinicians in regards to the medical impression on therapy methods for mRCC.
Previous analysis exhibits that issue disengaging from unfavorable (self-related) stimuli (i.e. unfavorable self-referential processing; NSP) is a vulnerability issue for melancholy (Gotlib & Joormann, 2010) and contributes to its recurrence (LeMoult, Kircanski, Prasad, & Gotlib, 2017). The Emotional Reversal Learning Task (ERLT) was designed to research this, and we examined its assemble validity by inducing social rejection, an etiological course of of melancholy, inside the ERLT mannequin.
We anticipated excluded individuals to have issue disengaging from NSP.We administered Cyberball to 130 individuals randomly assigned to the excluded or included situation. Participants then accomplished the ERLT: They selected a valence possibility (constructive or unfavorable), retrieved a reminiscence of the identical valence, after which had been rewarded or punished for his or her valence alternative.
For the primary section, retrieving a unfavorable reminiscence was probabilistically rewarded, and this action-outcome contingency was twice reversed through the process. We used Q-learning fashions to research studying charges.Excluded individuals had no extra issue disengaging from NSP than included individuals: Bayesian computational modeling recognized no distinction between situations concerning studying that retrieving unfavorable reminiscences was punished.
Exploratory analyses discovered that excluded individuals discovered the affiliation between retrieving constructive reminiscences and reward faster than included individuals, nevertheless.Doubts stay concerning whether or not individuals absolutely understood action-outcome contingencies, and we didn’t explicitly test whether or not individuals really retrieved reminiscences, which might have affected outcomes.
) Anti-LAMP3 antibody (Alexa-fluor 546) |
|||
| STJ170005 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
) Anti-LAMP3 antibody (Alexa-fluor 647) |
|||
| STJ170006 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
) Anti-IL3RA antibody (Alexa-fluor 488) |
|||
| STJ170009 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-IL3RA antibody (Alexa-fluor 546) |
|||
| STJ170010 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-IL3RA antibody (Alexa-fluor 647) |
|||
| STJ170011 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-CD207 antibody (Alexa-fluor 488) |
|||
| STJ170014 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-CD207 antibody (Alexa-fluor 546) |
|||
| STJ170015 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-CD207 antibody (Alexa-fluor 647) |
|||
| STJ170016 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-IL7R antibody (Alexa-fluor 488) |
|||
| STJ170020 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
) Anti-IL7R antibody (Alexa-fluor 546) |
|||
| STJ170021 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
) Anti-IL7R antibody (Alexa-fluor 647) |
|||
| STJ170022 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
 Anti-RPSA Alexa Fluor® 488 |
|||
| A4-829-C100 | ExBio | 0.1 mg | EUR 310 |
 mPEG-FITC,350 |
|||
| FL001044-350-100mg | Biochempeg | 100mg | EUR 519 |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
) Goat anti Mouse IgG1 (Alexa Fluor 488) |
|||
| 43R-1649 | Fitzgerald | 500 ug | EUR 570 |
|
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488) |
|||
 Anti-Hu CD16 Alexa Fluor® 488 |
|||
| A4-646-T100 | ExBio | 100 tests | EUR 269 |
 Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid] |
|||
| 1795 | AAT Bioquest | 10 mg | EUR 393 |
 (Alexa Fluor 594)) Donkey anti Goat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID005AF | Fitzgerald | 500 ug | EUR 338 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 594)) Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID022AF | Fitzgerald | 500 ug | EUR 364 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 647)) Donkey anti Goat IgG (H + L) (Alexa Fluor 647) |
|||
| 43R-ID028AF | Fitzgerald | 500 ug | EUR 430 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647) |
|||
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID047AF | Fitzgerald | 500 ug | EUR 462 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 594)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-ID056AF | Fitzgerald | 500 ug | EUR 343 |
|
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
|||
 (Alexa Fluor 647)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 647) |
|||
| 43R-ID060AF | Fitzgerald | 300 ug | EUR 425 |
|
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647) |
|||
 (Alexa Fluor 594)) Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-IR016AF | Fitzgerald | 1 mg | EUR 281 |
|
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
|||
 AF488-streptavidin conjugate [Streptavidin, Alexa Fluor™ 488 Conjugate] |
|||
| 16891 | AAT Bioquest | 1 mg | EUR 176 |
 AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
|||
| 16892 | AAT Bioquest | 1 mg | EUR 176 |
 AF488 Phalloidin [equivalent to Alexa Fluor® 488 phalloidin] |
|||
| 23153 | AAT Bioquest | 300 Tests | EUR 306 |
 AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
|||
| 23158 | AAT Bioquest | 300 Tests | EUR 306 |
 Anti-Hu CD72 Alexa Fluor® 488 |
|||
| A4-310-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Bov CD9 Alexa Fluor® 488 |
|||
| A4-354-C100 | ExBio | 0.1 mg | EUR 269 |
 Anti-Hu CD30 Alexa Fluor® 700 |
|||
| A7-455-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Hu CD94 Alexa Fluor® 700 |
|||
| A7-727-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Hu CD56 Alexa Fluor® 700 |
|||
| A7-789-T100 | ExBio | 100 tests | EUR 269 |
 RNF14 antibody |
|||
| 70R-36865 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit Polyclonal RNF14 antibody |
|||
 RNF14 Antibody |
|||
| AF0819 | Affbiotech | 200ul | EUR 304 |
|
Description: RNF14 Antibody detects endogenous levels of RNF14. |
|||
RNF14 Antibody |
|||
| ABD4026 | Lifescience Market | 100 ug | EUR 438 |
RNF14 Antibody |
|||
| ABF0819 | Lifescience Market | 100 ug | EUR 438 |
RNF14 Antibody |
|||
| DF4026 | Affbiotech | 200ul | EUR 304 |
|
Description: RNF14 Antibody detects endogenous levels of total RNF14. |
|||
RNF14 Antibody |
|||
| 1-CSB-PA080036 | Cusabio |
|
|
|
Description: A polyclonal antibody against RNF14. Recognizes RNF14 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/40000 |
|||
RNF14 Antibody |
|||
| 1-CSB-PA409215 | Cusabio |
|
|
|
Description: A polyclonal antibody against RNF14. Recognizes RNF14 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
RNF14 Antibody |
|||
| 40324-100ul | SAB | 100ul | EUR 252 |
 Alexa Fluor 594–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 594–conjugated |
|||
| S0005 | Affbiotech | 200ul | EUR 376 |
 Alexa Fluor 594–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 594–conjugated |
|||
| S0006 | Affbiotech | 200ul | EUR 376 |
 Alexa Fluor 647–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0013 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 647–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0014 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0017 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0018 | Affbiotech | 200ul | EUR 304 |
 Mouse pre-microRNA Expression Construct mir-350 |
|||
| MMIR-350-PA-1 | SBI | Bacterial Streak | EUR 684 |
 Monoclonal Antibody (104G4) (Alexa Fluor<sup>®</sup> 488)) Anti-LAMP3 (human) Monoclonal Antibody (104G4) (Alexa Fluor® 488) |
|||
| M09406 | BosterBio | 100ug | EUR 565 |
|
Description: Mouse Monoclonal LAMP3 (human) Antibody (104G4) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
|||
 Anti-RNF14 antibody |
|||
| STJ119441 | St John's Laboratory | 100 µl | EUR 277 |
 RNF14 Conjugated Antibody |
|||
| C40324 | SAB | 100ul | EUR 397 |
 (Fab 2) (Alexa Fluor 594)) Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
|||
| 43R-ID012AF | Fitzgerald | 300 ug | EUR 410 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
|||
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488 |
|||
| A4-686-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488 |
|||
| A4-712-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488 |
|||
| A4-730-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488 |
|||
| A4-737-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647 |
|||
| A6-686-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647 |
|||
| A6-712-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647 |
|||
| A6-730-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647 |
|||
| A6-737-C100 | ExBio | 0.1 mg | EUR 269 |
, Alexa Fluor® 594 Conjugated) Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
|||
| Ab8011-001 | GenDepot | 1mg | EUR 334 |
, Alexa Fluor® 488 Conjugated) Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated |
|||
| Ab8032-001 | GenDepot | 0.5mg | EUR 435 |
 anti-RNF14 |
|||
| YF-PA16427 | Abfrontier | 50 ul | EUR 363 |
|
Description: Mouse polyclonal to RNF14 |
|||
anti-RNF14 |
|||
| YF-PA16428 | Abfrontier | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal to RNF14 |
|||
anti-RNF14 |
|||
| YF-PA25376 | Abfrontier | 50 ul | EUR 334 |
|
Description: Mouse polyclonal to RNF14 |
|||
 RNF14 siRNA |
|||
| 20-abx931707 | Abbexa |
|
|
RNF14 siRNA |
|||
| 20-abx931708 | Abbexa |
|
|
 Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor<sup>®</sup> 488)) Anti-Langerin (human) Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor® 488) |
|||
| M02316 | BosterBio | 100ug | EUR 580 |
|
Description: Mouse Monoclonal Langerin (human) Antibody (DCGM4/122D5) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
|||
 Anti-RNF14/Ara54 Antibody |
|||
| A08956 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal RNF14/Ara54 Antibody. Validated in WB and tested in Human, Mouse, Rat. |
|||
 RNF14 Blocking Peptide |
|||
| AF0819-BP | Affbiotech | 1mg | EUR 195 |
) Anti-RNF14 (4G9) |
|||
| YF-MA16945 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to RNF14 |
|||
RNF14 Blocking Peptide |
|||
| DF4026-BP | Affbiotech | 1mg | EUR 195 |
 RNF14 cloning plasmid |
|||
| CSB-CL887008HU-10ug | Cusabio | 10ug | EUR 233 |
|
Description: A cloning plasmid for the RNF14 gene. |
|||
 RNF14 Rabbit pAb |
|||
| A17311-100ul | Abclonal | 100 ul | EUR 308 |
RNF14 Rabbit pAb |
|||
| A17311-200ul | Abclonal | 200 ul | EUR 459 |
RNF14 Rabbit pAb |
|||
| A17311-20ul | Abclonal | 20 ul | EUR 183 |
RNF14 Rabbit pAb |
|||
| A17311-50ul | Abclonal | 50 ul | EUR 223 |
) Polyclonal RNF14 Antibody (C-term) |
|||
| APR04236G | Leading Biology | 0.1ml | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RNF14 (C-term). This antibody is tested and proven to work in the following applications: |
|||
 Human E3 ubiquitin- protein ligase RNF14, RNF14 ELISA KIT |
|||
| ELI-30255h | Lifescience Market | 96 Tests | EUR 824 |
 Mouse E3 ubiquitin- protein ligase RNF14, Rnf14 ELISA KIT |
|||
| ELI-38870m | Lifescience Market | 96 Tests | EUR 865 |
-Alexa 488 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG) |
|||
| 50336 | Alpha Diagnostics | 0.5 ml | EUR 225 |
-Alexa 594 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
|||
| 50337 | Alpha Diagnostics | 0.5 ml | EUR 225 |
) EBV antibody (gp250/350) |
|||
| 10-E40A | Fitzgerald | 200 ug | EUR 229 |
|
Description: Mouse monoclonal EBV antibody (gp250/350) |
|||
 p3*Flag-RNF14 Plasmid |
|||
| PVTB00422-2a | Lifescience Market | 2 ug | EUR 356 |
) RNF14 Recombinant Protein (Human) |
|||
| RP042943 | ABM | 100 ug | Ask for price |
) RNF14 Recombinant Protein (Mouse) |
|||
| RP168485 | ABM | 100 ug | Ask for price |
RNF14 Recombinant Protein (Mouse) |
|||
| RP168488 | ABM | 100 ug | Ask for price |
RNF14 Recombinant Protein (Mouse) |
|||
| RP168491 | ABM | 100 ug | Ask for price |
) RNF14 Recombinant Protein (Rat) |
|||
| RP226325 | ABM | 100 ug | Ask for price |
 Mouse RNF14 shRNA Plasmid |
|||
| 20-abx974884 | Abbexa |
|
|
 Human RNF14 shRNA Plasmid |
|||
| 20-abx956390 | Abbexa |
|
|
 ELISA kit, 96 tests, Quantitative) Glucagon Like Peptide 1, Active (GLP-1, 7-36/7-37) ELISA kit, 96 tests, Quantitative |
|||
| 350 | Alpha Diagnostics | 1 kit | EUR 834 |
 Antibody) Ring Finger Protein 14 (RNF14) Antibody |
|||
| 20-abx211788 | Abbexa |
|
|
Ring Finger Protein 14 (RNF14) Antibody |
|||
| 20-abx327781 | Abbexa |
|
|
Ring Finger Protein 14 (RNF14) Antibody |
|||
| abx145571-100ug | Abbexa | 100 ug | EUR 391 |
Ring Finger Protein 14 (RNF14) Antibody |
|||
| abx029683-400ul | Abbexa | 400 ul | EUR 523 |
Ring Finger Protein 14 (RNF14) Antibody |
|||
| abx029683-80l | Abbexa | 80 µl | EUR 286 |
 mPEG-SH,350 |
|||
| 33-MF001003-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-CHO,350 |
|||
| 33-MF001004-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-AlKyne,350 |
|||
| 33-MF001007-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-COOH?350 |
|||
| 33-MF001017-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-Silane,350 |
|||
| 33-MF001020-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-Epoxide,350 |
|||
| 33-MF001021-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-MAL,350 |
|||
| 33-MF001022-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-SC,350 |
|||
| 33-MF001023-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-Biotin,350 |
|||
| 33-MF001041-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-DSPE,350 |
|||
| 33-MF001096-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
 mPEG-AA,350 |
|||
| 33-MF001121-350 | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
) Polyclonal THOC5 Antibody (aa338-350) |
|||
| APR02330G | Leading Biology | 0.05mg | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human THOC5 (aa338-350). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal TPX2 Antibody (aa301-350) |
|||
| APR02795G | Leading Biology | 0.05ml | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TPX2 (aa301-350). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal TLR5 Antibody (aa300-350) |
|||
| APR02821G | Leading Biology | 0.05mg | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TLR5 (aa300-350). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal TBKBP1 Antibody (aa300-350) |
|||
| APR02895G | Leading Biology | 0.05mg | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TBKBP1 (aa300-350). This antibody is tested and proven to work in the following applications: |
|||
We didn’t discover assist for the assemble validity of the ERLT when utilizing social exclusion to mannequin depressogenic improvement inside the ERLT.
